Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G Wierda,Kathleen A Dorritie,Javier Munoz,Deborah M Stephens,Scott R Solomon,Heidi H Gillenwater,Lucy Gong,Lin Yang,Ken Ogasawara,Jerill Thorpe,Tanya Siddiqi

doi:10.1182/blood-2020-140622

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G Wierda, Kathleen A Dorritie + Show 9 more

Open Access

https://doi.org/10.1182/blood-2020-140622

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 41

Affiliation: The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, Huntsman Cancer Institute, Northside Hospital, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Italy), City Of Hope National Medical Center

#Equity Holder In Publicly-traded Company #CD19-directed Chimeric Antigen Receptor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.